Skip to Content
 

News: Journal Watch

Journal Watch

Thursday, November 30th, 2023

Clue to gastric cancer discovered Fibroblast cells play key roles in the repair of damaged tissue and in pathological scarring. James Goldenring, MD, PhD, and colleagues have uncovered evidence of their direct involvement in the development of gastric cancer. The findings, published May 15 in the journal Gastroenterology, could lead to novel interventions to prevent […]

Journal Watch

Wednesday, April 26th, 2023

Resources crucial for lung cancer screening A Veterans Health Administration project that provided resources for lung cancer screening programs increased the number of veterans screened, according to a study published in the September 2022 issue of the journal CHEST. The researchers found that the demonstration project centers screened about 18 veterans per 1,000 eligible veterans […]

Journal Watch

Monday, November 7th, 2022

Matching therapies to subtypes of EGFR-mutated lung cancer New research from Vanderbilt investigators suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small cell lung cancers. EGFR exon 19 deletion mutations are the most common EGFR mutations in patients with lung cancer. However, the term “exon 19 […]

Journal Watch

Friday, April 29th, 2022

World Trade Center responders at higher risk for blood cancer-associated mutations Scientists from Vanderbilt-Ingram Cancer Center (VICC) collaborated with researchers from New York to determine that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease, according to a study published March […]

Journal Watch

Thursday, September 30th, 2021

People at high genetic risk for colorectal cancer benefit more from lifestyle changes People with a high polygenic risk score for colorectal cancer could benefit more by preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American […]

Journal Watch

Monday, March 1st, 2021

New strategy for reducing tumor growth Ann Richmond, PhD, and colleagues have discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma. The findings, reported Dec. 18, 2020, in the journal Cancer Immunology Research, add mechanistic insight and support for the therapeutic […]

Journal Watch

Wednesday, September 23rd, 2020

Study finds AI can categorize cancer risk of lung nodules Computed tomography scans for people at risk for lung cancer lead to earlier diagnoses and improve survival rates, but they can also lead to overtreatment when suspicious nodules turn out to be benign. A study for which Pierre Massion, MD, was the lead author published […]

Journal Watch

Wednesday, January 15th, 2020

New prostate cancer treatment concept Prostate cancer, the second leading cause of cancer-related death for men in the United States, is poorly responsive to immunotherapy. Recent clinical trials have hinted that combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer. Austin Kirschner, MD, PhD, and colleagues combined radiotherapy with […]

Journal Watch

Friday, August 2nd, 2019

Cancer prevention drug also disables H. pylori bacterium A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer. Keith Wilson, MD, and J. Carolina Sierra, PhD, reported in the March 12 issue of Proceedings of the […]

Journal Watch

Thursday, January 3rd, 2019

Glutamine metabolism affects T cell signaling & function The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered. They show that a drug that inhibits glutamine metabolism — currently in clinical trials as an anticancer agent — might also […]

Next Page »